BN Manohar appointed as CEO of Stempeutics
Stempeutics Research private Ltd, a group company of Manipal Education & Medical Group, a leading stem cell company developing stem cell based medicinal products has promoted Mr. BN Manohar, formerly President as the Chief Executive Officer of the company.
Tweet-- Stempeutics Research private Ltd, a group company of Manipal Education & Medical Group, a leading stem cell company developing stem cell based medicinal products has promoted Mr. BN Manohar, formerly President as the Chief Executive Officer of the company
Commenting on his appointment Mr Manohar, CEO, Stempeutics a Manipal Education and Medical Group entity, said, "I have been associated with Stempeutics for long time. Being a part of the strong leadership team, I look forward to working with them to develop and bring the first stem cell product to the market and help execute the whole range of activities in which we operate." He will continue to be responsible for leading, developing; and implementing Stempeutics strategies which will shape future business delivery and also contribute to the achievement of the Company's strategic and financial objectives.
Manohar joined Manipal Education & Medical Group (MEMG) in 2002 as Chief Executive Officer- Manipal Infocom - a BPO Organization of MEMG. He made a significant contribution to the migration of the Call Center business into Manipal - Omega Healthcare BPO JV.
He has handled multiple roles in MEMG as CIO & Chief Executive - Strategic Projects, In April 2006 he was appointed as Chief Executive - Manipal Universal Learning, where he was responsible for establishing and propping up the new Education Services business consisting of On Line Assessment & Testing business, Vocational Education business, Engineering Twinning Education Program and E-content development.
Manohar has worked in Lucas-TVS, W.S Industries as a Systems Analyst, Wipro GE Medical Systems as Manager - Information Management, Wipro GE Medical Systems as Manager - Information Management.
A B.E graduate from Regional Engineering College - Trichy, in 1977 and a M.E graduate from Guindy Engg College, University of Madras in 1979, Manohar went on to enter the Indian Government Services. He served in Overseas Communication Services and Defence R&D organization for four years.
Notes to Editor
Stempeutics Research Pvt. Ltd
Stempeutics Research Private Limited (Stempeutics) a group company of Manipal Education & Medical Group is a leading stem cell company developing stem cell based medicinal products, with facilities in Bangalore and Manipal (India) as well as in Kuala Lumpur (Malaysia). The company is in the process of bringing the first stem cell therapy product to the Indian market.
Stempeutics has completed pre clinical studies demonstrating the appropriate safety profile of human bone marrow-derived ex vivo cultured adult mesenchymal stem cells in allogenic settings.
Stempeutics obtained Drugs Controller General of India (DCGI) / Indian Council of Medical Research (ICMR) approval for conducting multi centric phase I/II combined double blind randomized allogenic clinical trials (on-going) for its two most advanced programs, indicated in acute myocardial infarction (AMI) and critical limb ischemia (CLI). This is the FIRST allogenic stem cell clinical trial approved in India. A phase IIb/III study is planned to be conducted in India in 2010; another phase III study will be planned outside India. This second phase III is likely to be supportive for the registration of the product in ASEAN countries.
In addition, several programs are currently awaiting DCGI approval for various indications including chronic obstructive pulmonary disease, dilated cardiomyopathy, liver cirrhosis, osteoarthritis and diabetes mellitus. In Malaysia Stempeutics has obtained Ministry of Health approval for cerebral stroke clinical trials. Stempeutics long-term objective is to market its products in the European and North American markets.
For more information visit www.stempeutics.com